Publication

Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL)

Arabpour, M., Poelstra, K., Helfrich, W., Bremer, E. & Haisma, H. J., 2014, In : Journal of gene medicine. 16, 9-10, p. 281-290 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Arabpour, M., Poelstra, K., Helfrich, W., Bremer, E., & Haisma, H. J. (2014). Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL). Journal of gene medicine, 16(9-10), 281-290. https://doi.org/10.1002/jgm.2776

Author

Arabpour, Mohammad ; Poelstra, Klaas ; Helfrich, Wijnand ; Bremer, Edwin ; Haisma, Hidde J. / Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL). In: Journal of gene medicine. 2014 ; Vol. 16, No. 9-10. pp. 281-290.

Harvard

Arabpour, M, Poelstra, K, Helfrich, W, Bremer, E & Haisma, HJ 2014, 'Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL)', Journal of gene medicine, vol. 16, no. 9-10, pp. 281-290. https://doi.org/10.1002/jgm.2776

Standard

Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL). / Arabpour, Mohammad; Poelstra, Klaas; Helfrich, Wijnand; Bremer, Edwin; Haisma, Hidde J.

In: Journal of gene medicine, Vol. 16, No. 9-10, 2014, p. 281-290.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Arabpour M, Poelstra K, Helfrich W, Bremer E, Haisma HJ. Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL). Journal of gene medicine. 2014;16(9-10):281-290. https://doi.org/10.1002/jgm.2776


BibTeX

@article{6e8ee927a8484530b8f4f7a36312bf68,
title = "Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL)",
abstract = "BackgroundProgressive liver fibrosis is the result of chronic liver injury and is characterized by the excessive accumulation of extracellular matrix that may result in liver failure. Activated hepatic stellate cells are known to play a central role in this process and their elimination is a crucial step towards the resolution and reversion of liver fibrosis. In the present study, we investigated the potential application of an anti-epidermal growth factor receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL) fusion protein in the targeted elimination of activated hepatic stellate cells.MethodsActivated hepatic stellate cells (LX2 cells) were treated by adenovirus-derived scFv425-sTRAIL to evaluate its effect on the viability and extracellular matrix production of this type of cells.ResultsIn vitro treatment of activated hepatic stellate cells with scFv425-sTRAIL induced a significant reduction in viability (up to 100{\%} reduction) and extracellular matrix production (60{\%} reduction), yet no significant effect was observed on hepatic parenchymal cells. Blockage of the epidermal growth factor receptor (EGFR) by a monoclonal antibody significantly reduced the effectiveness of scFv425-sTRAIL in activated hepatic stellate cells, whereas a reduced effectivity was also observed after inhibition of the caspase pathway.ConclusionsEvidence is presented for the successful application of the scFv425-sTRAIL fusion protein in the targeted elimination of activated hepatic stellate cells via EGFR and simultaneous activation of the caspase pathway. scFv425-sTRAIL may thus represent a new therapeutic compound against liver fibrosis. Copyright (c) 2014 John Wiley & Sons, Ltd.",
keywords = "EGFR, liver fibrosis, targeted therapy, TRAIL, STRAIL FUSION PROTEIN, LIVER FIBROSIS, MEDIATED APOPTOSIS, INHIBITION, INDUCTION, CANCER, PROLIFERATION, SPECIFICITY",
author = "Mohammad Arabpour and Klaas Poelstra and Wijnand Helfrich and Edwin Bremer and Haisma, {Hidde J.}",
note = "This article is protected by copyright. All rights reserved.",
year = "2014",
doi = "10.1002/jgm.2776",
language = "English",
volume = "16",
pages = "281--290",
journal = "Journal of gene medicine",
issn = "1099-498X",
publisher = "Wiley",
number = "9-10",

}

RIS

TY - JOUR

T1 - Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL)

AU - Arabpour, Mohammad

AU - Poelstra, Klaas

AU - Helfrich, Wijnand

AU - Bremer, Edwin

AU - Haisma, Hidde J.

N1 - This article is protected by copyright. All rights reserved.

PY - 2014

Y1 - 2014

N2 - BackgroundProgressive liver fibrosis is the result of chronic liver injury and is characterized by the excessive accumulation of extracellular matrix that may result in liver failure. Activated hepatic stellate cells are known to play a central role in this process and their elimination is a crucial step towards the resolution and reversion of liver fibrosis. In the present study, we investigated the potential application of an anti-epidermal growth factor receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL) fusion protein in the targeted elimination of activated hepatic stellate cells.MethodsActivated hepatic stellate cells (LX2 cells) were treated by adenovirus-derived scFv425-sTRAIL to evaluate its effect on the viability and extracellular matrix production of this type of cells.ResultsIn vitro treatment of activated hepatic stellate cells with scFv425-sTRAIL induced a significant reduction in viability (up to 100% reduction) and extracellular matrix production (60% reduction), yet no significant effect was observed on hepatic parenchymal cells. Blockage of the epidermal growth factor receptor (EGFR) by a monoclonal antibody significantly reduced the effectiveness of scFv425-sTRAIL in activated hepatic stellate cells, whereas a reduced effectivity was also observed after inhibition of the caspase pathway.ConclusionsEvidence is presented for the successful application of the scFv425-sTRAIL fusion protein in the targeted elimination of activated hepatic stellate cells via EGFR and simultaneous activation of the caspase pathway. scFv425-sTRAIL may thus represent a new therapeutic compound against liver fibrosis. Copyright (c) 2014 John Wiley & Sons, Ltd.

AB - BackgroundProgressive liver fibrosis is the result of chronic liver injury and is characterized by the excessive accumulation of extracellular matrix that may result in liver failure. Activated hepatic stellate cells are known to play a central role in this process and their elimination is a crucial step towards the resolution and reversion of liver fibrosis. In the present study, we investigated the potential application of an anti-epidermal growth factor receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL) fusion protein in the targeted elimination of activated hepatic stellate cells.MethodsActivated hepatic stellate cells (LX2 cells) were treated by adenovirus-derived scFv425-sTRAIL to evaluate its effect on the viability and extracellular matrix production of this type of cells.ResultsIn vitro treatment of activated hepatic stellate cells with scFv425-sTRAIL induced a significant reduction in viability (up to 100% reduction) and extracellular matrix production (60% reduction), yet no significant effect was observed on hepatic parenchymal cells. Blockage of the epidermal growth factor receptor (EGFR) by a monoclonal antibody significantly reduced the effectiveness of scFv425-sTRAIL in activated hepatic stellate cells, whereas a reduced effectivity was also observed after inhibition of the caspase pathway.ConclusionsEvidence is presented for the successful application of the scFv425-sTRAIL fusion protein in the targeted elimination of activated hepatic stellate cells via EGFR and simultaneous activation of the caspase pathway. scFv425-sTRAIL may thus represent a new therapeutic compound against liver fibrosis. Copyright (c) 2014 John Wiley & Sons, Ltd.

KW - EGFR

KW - liver fibrosis

KW - targeted therapy

KW - TRAIL

KW - STRAIL FUSION PROTEIN

KW - LIVER FIBROSIS

KW - MEDIATED APOPTOSIS

KW - INHIBITION

KW - INDUCTION

KW - CANCER

KW - PROLIFERATION

KW - SPECIFICITY

U2 - 10.1002/jgm.2776

DO - 10.1002/jgm.2776

M3 - Article

VL - 16

SP - 281

EP - 290

JO - Journal of gene medicine

JF - Journal of gene medicine

SN - 1099-498X

IS - 9-10

ER -

ID: 13590449